Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ocugen

0.7650
+0.02693.64%
Post-market: 0.76990.0049+0.64%19:59 EDT
Volume:3.90M
Turnover:2.99M
Market Cap:223.39M
PE:-3.84
High:0.7800
Open:0.7410
Low:0.7410
Close:0.7381
Loading ...

Ocugen Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
06 Mar

Ocugen (OCGN) Q4 2024 Earnings Call Transcript

Motley Fool Transcribing
·
06 Mar

OCGN Earnings: Ocugen Stock Jumps on Q4 Results & Development Updates

TIPRANKS
·
05 Mar

Ocugen: Q4 Earnings Snapshot

Associated Press Finance
·
05 Mar

Ocugen reports Q4 EPS (5c), consensus (5c)

TIPRANKS
·
05 Mar

Ocugen Q4 2024 GAAP EPS $(0.05), Inline, Sales $764.000K Beat $300.000K Estimate. Cash And Equivalents $58.8M

Benzinga
·
05 Mar

Ocugen Q4 Profit From Operations USD -13.84 Million

THOMSON REUTERS
·
05 Mar

Ocugen Q4 Net Income USD -13.88 Million

THOMSON REUTERS
·
05 Mar

Ocugen Inc: Ocu400 Remains on Track to Meet 1H 2025 Recruitment Completion and Potential Bla/Maa Filings by Mid-2026

THOMSON REUTERS
·
05 Mar

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
05 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
05 Mar

Ocugen Inc. Stock Falls Tuesday, Underperforms Market

Dow Jones
·
05 Mar

Noble Financial Sticks to Its Buy Rating for Ocugen (OCGN)

TIPRANKS
·
04 Mar

Ocugen Inc. Stock Slips 7.2%, Underperforms Market

Dow Jones
·
04 Mar

Ocugen's Gene Therapies Receive EMA Advanced Therapy Classification for Vision Loss Treatment

MT Newswires Live
·
04 Mar

BRIEF-Ocugen Announces Positive Opinion Of EMA’S Committee For Advanced Therapies For ATMP Classification

Reuters
·
03 Mar

Ocugen Announces Positive Opinion of Ema’s Committee for Advanced Therapies for Atmp Classification for Novel Modifier Gene Therapy Candidate Ocu410 for Geographic Atrophy and Ocu410st for Stargardt Disease

THOMSON REUTERS
·
03 Mar

Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease

GlobeNewswire
·
03 Mar

Ocugen Inc expected to post a loss of 5 cents a share - Earnings Preview

Reuters
·
03 Mar

Analysts Offer Insights on Healthcare Companies: Ventyx Biosciences (VTYX) and Ocugen (OCGN)

TIPRANKS
·
02 Mar